A study led by the Vall d'Hebron Research Institute (VHIR) demonstrates the causal role of air pollution in ventricular arrhythmias and identifies a possible therapeutic strategy based on antioxidants.

The REACH5 study confirms that the efficacy and safety results observed in previous studies are maintained after three years of follow-up.

With women representing 66% of its workforce, the Institute is promoting a new Equality Plan to advance equity in research and leadership.

Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.

In-depth knowledge of tumours helps identify specific alterations and enables the provision of targeted therapies for each patient.

The study results show that the local presence of IL-1β promotes the development of myeloid cells with an immunosuppressive function.

The charitable initiative created in honor of Pol is supporting a research project aimed at identifying therapeutic targets to treat a rare type of leukemia.

The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.

The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.

The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.

The study will validate the safety of a novel topical ocular administration route for sitagliptin.

The document provides a comprehensive evaluation of current knowledge on this type of cancer affecting the bile ducts.

Vall d’Hebron is part of the Consorcio INTERCOVID, which has analyzed over 6,500 pregnancies in 18 countries and observed a significant reduction in the risk of preeclampsia associated with vaccination.

The charitable initiative will allocate all funds to research on pediatric nervous system tumors carried out at the Vall d’Hebron Research Institute

A large-scale study involving Vall d’Hebron confirms the genetic relatedness among 14 different psychiatric disorders and groups them into five new families, paving the way for new treatments targeting their shared underlying genetic causes

The study, led by Dr. Lucas Moreno and University of Birmingham shows that the combined administration of chemotherapy and immunotherapy with the antibody dinutuximab beta achieves a better treatment response.

The donation will support a project investigating new therapeutic approaches in pediatric brain tumors

The €15,000 donation will boost research into this very rare type of childhood cancer.

On the occasion of the International Day of Women and Girls in Science, celebrated every 11 February, around one hundred children aged between 10 and 12 have discovered the laboratories of the VHIR.

The association has donated €15,088 to the Childhood Cancer and Blood Disorders group at VHIR to improve the treatment of rhabdomyosarcoma.

The Iris Association has made a €14,499 donation to the Childhood Cancer and Hematological Diseases Group at the Vall d’Hebron Research Institute (VHIR).

Vall d’Hebron has taken part in a clinical trial whose results show improvements in endometrial regeneration and reproductive outcomes in patients with Asherman syndrome who had not responded to previous surgery.

A VHIR team travels to Angola to test, under real-world conditions, an innovative device designed for mass diagnosis in resource-limited settings.

This VHIR initiative promotes well-being, empathy and community participation in Barcelona neighbourhoods through an intergenerational model